Venue: Boston

Location: Boston, United States

Event Date/Time: Jun 21, 2011 End Date/Time: Jun 23, 2011
Report as Spam


Everything has changed. In less than twelve months the industry has transformed and the major players are waking up to the exciting prospects of cancer immunotherapy. Amgen’s recent acquisition of Biovex merely underlines the huge potential of this exciting field and marks yet more investment into these ground breaking technologies.

Designed by thought leaders at Merck Serono, GSK, Dendreon, BMS and FDA among others, the 2nd World Cancer Vaccine Summit will provide the perfect mix of attendees from early research, clinical, regulatory, and business development to discuss how to capitalize on the huge commercial promise of Provenge and other cancer vaccines.

Already confirmed:

• Helen Sabzevari, Global Head Oncology-Immunology, Merck Serono
• Jeffrey Schlom, Chief Laboratory of Tumor Immunology & Biology, National Cancer Institute
• Peter Bross, Medical Review Officer, Office of Cellular, Tissue & Gene Therapy, FDA
• Claudia Palena, Head, Immunoregulation Group, National Cancer Institute
• Alex Kudrin, Medical Director, Gastroenterology, Urology & Musculoskeletal, Takeda R&D
• David Kirn, President and CEO, Jennerex Biotherapeutics

Event objectives

1. To deliver a useful, practical agenda that highlights the work being done in cancer vaccine development programs and shares approaches, barriers and successes.
2. To provide a platform for interactive discussions on the most appropriate endpoints and challenges surrounding clinical trial design. Strongly scientific and focused on overcoming difficulties in clinical development.
3. To analyze the commercial opportunities cancer vaccines offer. Potential returns, partnering and licensing possibilities and business strategies.
4. To deliver presentations that focus on navigating the approval process for cancer immunotherapy products. Illustrating the process with practically useful case studies and contribution from the FDA.

Who attends?

• VPs, Senior Directors, Heads of Marketing, Licensing & Business Development
• Scientists involved in Oncology Drug Development, Medical Affairs & Clinical Research and Development
• Venture Capitalists
• Consultants and Regulators
All representing the major CROs, major oncology pharmaceuticals, cancer vaccine biotechs and investigators in the field.

For more information or to register, simply:

Call: +1 212 537 5898
Email: info@hansonwade.com